ES2148170T3 - Derivados de xantina. - Google Patents

Derivados de xantina.

Info

Publication number
ES2148170T3
ES2148170T3 ES92901589T ES92901589T ES2148170T3 ES 2148170 T3 ES2148170 T3 ES 2148170T3 ES 92901589 T ES92901589 T ES 92901589T ES 92901589 T ES92901589 T ES 92901589T ES 2148170 T3 ES2148170 T3 ES 2148170T3
Authority
ES
Spain
Prior art keywords
substituted
group
unsubstituted
formula
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901589T
Other languages
English (en)
Inventor
David Glynn Smith
Derek Richard Buckle
Ashley Edward Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909027899A external-priority patent/GB9027899D0/en
Priority claimed from GB909027752A external-priority patent/GB9027752D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of ES2148170T3 publication Critical patent/ES2148170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

UN COMPUESTO DE LA FORMULA (I) O, SI ES APROPIADO, UNA SAL DEL MISMO FARMACEUTICAMENTE ACEPTABLE, EN LA QUE R1 Y R2 CADA UNO INDEPENDIENTEMENTE REPRESENTAN UN GRUPO ALQUILO O UNA MITAD DE LA FORMULA (A): -(CH2)M-A, EN LA QUE M REPRESENTA CERO O UN ENTERO 1,2 O 3 Y A REPRESENTA UN RADICAL HIDROCARBONO CICLICO SUSTITUIDO O INSUSTITUIDO; R3 REPRESENTA HIDROGENO, NO2 O UN ATOMO DE HALOGENO, UN GRUPO ALCOXI O UN GRUPO DE LA FORMULA NRSRT EN LA QUE RS Y RT CADA UNO INDEPENDIENTEMENTE REPRESENTAN HIDROGENO O ALQUILO O RS Y RT JUNTOS CON EL NITROGENO AL CUAL ESTAN UNIDOS, FORMAN UN GRUPO FTALIMIDO, ESTANDO SUSTITUIDO O INSUSTITUIDO EL GRUPO FTALIMIDO EN LA MITAD FENILENO, O R3 REPRESENTA UNA MITAD DE LA FORMULA (B), EN LA QUE R5 REPRESENTA ALQUILO SUSTITUIDO O INSUSTITUIDO O UN GRUPO ARILO SUSTITUIDO O INSUSTITUIDO; Y R6 REPRESENTA HIDROGENO O UN GRUPO SO2R7 EN LA QUE R7 REPRESENTA ALQUILO SUSTITUIDO O INSUSTITUIDO, UN GRUPO ARILO SUSTITUIDO O INSUSTITUIDO; R4 REPRESENTA SO2R8, EN LA QUE R8 REPRESENTA ALQUILO SUSTITUIDO O INSUSTITUIDO O UN GRUPO ARILO SUSTITUIDO O INSUSTITUIDO, O, CUANDO R3 REPRESENTA UNA MITAD DE LA FORMULA ARRIBA DEFINIDA (B), ENTONCES R4 REPRESENTA HIDROGENO O UN GRUPO ALQUILO SUSTITUIDO O INSUSTITUIDO O UN GRUPO BENCILO SUSTITUIDO O INSUSTITUIDO EN EL ANILLO FENILO, UN PROCESO PARA PREPARAR SEMEJANTE COMPUESTO, UNA COMPOSICION QUE COMPRENDE TAL COMPUESTO Y EL USO DE SEMEJANTE COMPUESTO Y COMPOSICION EN MEDICINA.
ES92901589T 1990-12-21 1991-12-19 Derivados de xantina. Expired - Lifetime ES2148170T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027899A GB9027899D0 (en) 1990-12-21 1990-12-21 Novel compounds
GB909027752A GB9027752D0 (en) 1990-12-21 1990-12-21 Novel compounds

Publications (1)

Publication Number Publication Date
ES2148170T3 true ES2148170T3 (es) 2000-10-16

Family

ID=26298155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901589T Expired - Lifetime ES2148170T3 (es) 1990-12-21 1991-12-19 Derivados de xantina.

Country Status (14)

Country Link
US (1) US5409934A (es)
EP (1) EP0563168B1 (es)
JP (1) JPH06504534A (es)
KR (1) KR930703319A (es)
AT (1) ATE194345T1 (es)
AU (1) AU649091B2 (es)
CA (1) CA2098846A1 (es)
DE (1) DE69132291T2 (es)
ES (1) ES2148170T3 (es)
IE (1) IE914502A1 (es)
MX (1) MX9102766A (es)
NZ (1) NZ241158A (es)
PT (1) PT99919B (es)
WO (1) WO1992011260A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
CA2218548A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
US5981549A (en) * 1997-02-14 1999-11-09 Synapse Pharmaceutical International Method for controlling or alleviating the symptoms of respiratory disease and allergies
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
US6133273A (en) * 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
US6221874B1 (en) * 1998-05-08 2001-04-24 American Home Products Corporation Method of treating bone loss by stimulation of calcitonin
WO2001016134A1 (en) * 1999-08-31 2001-03-08 Vanderbilt University Selective antagonists of a2b adenosine receptors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP3998118B2 (ja) * 2000-10-10 2007-10-24 本田技研工業株式会社 電動車両
CA2457944C (en) * 2001-08-28 2009-09-29 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
WO2003042216A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
US6924140B2 (en) * 2002-06-14 2005-08-02 Lewis J. Daly Closed loop work station bioremediation using mini-reactor cartridges
AU2003231805A1 (en) * 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
EP1648895B1 (en) * 2003-07-31 2007-05-30 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
CN1905860A (zh) * 2003-11-21 2007-01-31 先灵公司 磷酸二酯酶v抑制剂制剂
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2009073210A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
PE20110834A1 (es) 2008-12-06 2011-12-14 Intra Cellular Therapies Inc DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900474A (en) * 1973-05-14 1975-08-19 Kendall & Co Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916469A1 (de) * 1989-05-20 1990-11-22 Basf Ag Sulfonamide
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
MX9102766A (es) 1992-09-01
DE69132291T2 (de) 2000-12-14
EP0563168B1 (en) 2000-07-05
KR930703319A (ko) 1993-11-29
EP0563168A1 (en) 1993-10-06
US5409934A (en) 1995-04-25
ATE194345T1 (de) 2000-07-15
DE69132291D1 (en) 2000-08-10
AU9122791A (en) 1992-07-22
IE914502A1 (en) 1992-07-01
CA2098846A1 (en) 1992-06-22
PT99919A (pt) 1992-12-31
PT99919B (pt) 1999-06-30
WO1992011260A1 (en) 1992-07-09
NZ241158A (en) 1994-12-22
AU649091B2 (en) 1994-05-12
JPH06504534A (ja) 1994-05-26

Similar Documents

Publication Publication Date Title
ES2148170T3 (es) Derivados de xantina.
NO901300D0 (no) Behandling og forbindelser.
HUP0300922A2 (hu) Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0464846T3 (da) Imidderivater og deres fremstilling og anvendelse
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES8400388A1 (es) Metodo de preparar compuestos aminoalcoil heterociclicos de de actividad farmaceutica.
DE69323630T2 (de) Benzokondensierte verbindungen
ES8102104A1 (es) Un procedimiento para la preparacion de nuevos derivados - hete rociclicos.
DE69003200D1 (de) Arylsubstituierte Aminderivate verwendbar in der Krebstherapie.
DK0607355T3 (da) Benzodiazepinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
IL106387A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
SE8101464L (sv) 2-penem-3-karboxylsyraderivat, deras framstellning och anvendning
SE9603283D0 (sv) New compounds
DK0514442T3 (da) N-Phenyl-N-acetamidoglycinamider, deres fremstilling og lægemidler med indehold deraf
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
ES466366A1 (es) Un procedimiento para preparar derivados de metasulfonamido-benzamida.
ES8401456A1 (es) Procedimiento para la preparacion de 2-aminometilfenoles.
HUP9700954A2 (hu) Szubsztituált 1-naftoil-guanidin-származékok, előállításuk, valamint az e vegyületeket tartalmazó gyógyszerkészítmények
DK356287A (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
HUP9902041A2 (hu) Új kinoxalin-dion-származékok, a vegyületek előállítása és ezeket tartalmazó gyógyszerkészítmények
ES2056025A1 (es) Nuevos derivados de indol.
KR940014354A (ko) 신규2-페녹시피리미딘유도체,그의제조방법및제초제로서의그의용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 563168

Country of ref document: ES